In this review, we will focus on B cell abnormalities and the rationale behind B-cell depletion therapy with anti-CD20 monoclonal antibody (mAb), rituximab, will be explored including an evaluation of clinical and trial experience. Finally, we will discuss the mechanistic basis for considering alternative anti-CD20 mAbs.

2021年1月1日 · In this review, we will focus on B cell abnormalities and the rationale behind B-cell depletion therapy with anti-CD20 monoclonal antibody (mAb), rituximab, will be explored including an evaluation of clinical and trial experience. Finally, we will discuss the mechanistic basis for considering alternative anti-CD20 mAbs.

The clear clinical benefits of anti-CD20 mAb treatment in RA, particularly in patients refractory to other available treatments, has led to the expansion of anti-CD20 mAbs for other autoimmune diseases with both T cell and B cell etiology, including systemic lupus erythematosus (SLE) and multiple sclerosis (MS).

Rituximab (RTX), an anti-CD20 mAb, has been explored in SLE, given its B cell specificity and its efficacy in many other rheumatologic diseases. Belimumab (BEL), a mAb with specificity for B cell activating factor (BAFF), a vital B cell survival and differentiation factor, has also been explored in …

The CALIBRATE trial (combination of antibodies in lupus nephritis: belimumab and rituximab assessment of tolerance and efficacy) investigated the use of rituximab followed by belimumab in adult SLE. Anti-CD20 agents such as rituximab spare the early pre-B and plasma cells, as these B-cell populations do not express CD20 on their surfaces.50 ...

2024年2月6日 · cd20单抗(如利妥昔单抗[rtx])通常用于治疗严重或难治性系统性红斑狼疮(sle)。 新一代人源化CD20单抗，如奥法妥木单抗和奥瑞利珠单抗已被建议作为对 ...

Background: Anti-C20 monoclonal antibodies (MAb), such as rituximab, are commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE) but clinical outcomes are highly variable. We aimed to provide an update of a systematic review of predictive and prognostic factors of anti-CD20 MAb treatment in SLE.

This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab). Systemic lupus erythemaotsus (SLE) is an autoimmune disease involving multiple organ systems and characterized by anti-nuclear antibodies.

目的：探讨抗cd20单克隆抗体治疗重症系统性红斑狼疮（sle）的疗效，研究其临床治疗价值。 方法：将66例重症SLE患者随机分为治疗组（36例）和对照组（30例），在激素冲击疗法基础上，两

2020年6月15日 · At present, anti-CD20 monoclonal antibody treatments targeting systemic lupus erythematosus (SLE) are complex, variable, and often have disappointing outcomes. High levels of programmed cell death-1 (PD-1) and its ligands (PD-L1, PD-L2) or CD80/CD86 on B cell surfaces are markers of increased B cell activity.